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ABSTRACT 
Introduction: A national surveillance program (SIR) was intro- 
duced in 1996 in Argentina by the Antimicrobial Committee of 
the Argentinean Society for Microbiology to assess bacterial 
resistance, The present study reports the rates of nosocomial 
bacterial resistance found by this program. 
R/lethods: A 2-month point-prevalence study was conducted 
twice yearly (i.e., April-May and October-November) from 1996 
to 1998, by 27 Argentinean centers. Susceptibility testing was 
carried out by the disk diffusion method following the National 
Committee for Clinical Laboratory Standards guidelines. 
Results: In all, 6343 isolates recovered from 5603 inpatients 
(248-hr hospitalization) were included. Methicillin resistance was 
58% and 56% in Staphylococcus aureus and coagulase-neg- 
ative staphylococci (CNS), respectively. Although no van- 
comycin resistance was found in staphylococci, 2% and 8% 
of the S. aureus and CNS strains, respectively, proved resis- 
tant to teicoplanin. No ampicillin resistance was displayed by 
fnterococcus faecalis. High-level gentamicin and streptomycin 
resistance in enterococci were 33% and 37%, respectively. 
Acquired glycopeptide resistance in enterococci emerged in 
1997 (2%). lmipenem resistance in Acinetobacter spp and 
Pseudomonas aeruginosa was 9% and 21%, respectively. 
Among Enterobacteriaceae, 1% and 5% of the Klebsiella pneu- 
moniae and Enterobacter cloacae isolates, respectively, proved 
resistant to imipenem. Ceftazidime and cefepime resistance 
was found in 63% and 33% of the E. cloacae strains. 
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Resistance to extended-spectrum cephalosporins was shown 
by 48%, 26%, and 8% of the K. pneumoniae, Proteus mirabilis, 
and Escherichia co/i isolates, respectively. 
Conclusions: The alarming rates of resistance found in this 
study provide compelling evidence of the need for more ration- 
al use of antimicrobial agents in Argentina. 
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Nosocomial infections are a worrisome problem world- 
wide. In addition, antimicrobial resistance results in 
increased morbidity, mortality, and cost of health care. 
Thus, the establishment of a system for monitoring bac- 
terial resistance has became one of the most important 
supports recommended in the guidelines for the pre- 
vention of antimicrobial resistance in hospitals.’ Fur- 
thermore, information from routine susceptibility testing 
of bacterial isolates and surveillance of antibiotic resis- 
tance, which provides information on resistance trends, 
including emerging antibiotic resistance, is essential for 
clinical practice.* 
Unfortunately, various strategies applied in hospitals 
to prevent the spread of antibiotic resistance have not 
always resulted in increases of bacterial susceptibility to 
antibiotics.3 In fact, a number of different antimicrobial 
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agents have been rendered ineffective because of the 
selective pressure of antibiotics leading to the emergence 
of resistance.* Among the most relevant emerging resis- 
tance in hospitals from the United States and Europe are 
methicillin-resistant, and more recently, glycopeptide- 
resistant staphylococci, gentamicin- and glycopeptide- 
resistant enterococci, as well as the resistance to fluoro- 
quinolones, extended-spectrum cephalosporins, and 
carbapenem displayed by gram-negative bacilli.5 
The antibiotic susceptibility profiles of bacterial iso- 
lates are unknown in much of the developing world.6 
Despite several efforts made to design and establish a 
national surveillance system of nosocomial infections in 
Argentina, currently, there is no systematically controlled 
program. Therefore, reliable data on nosocomial infection 
rates from hospitals are scarce. Nevertheless, some data 
on antimicrobial resistance have been available in 
Argentina for several years.’ A national surveillance pro- 
gram (SIR) was introduced in 1996 in Argentina by the 
Antimicrobial Committee of the Argentinean Society for 
Microbiology to assess bacterial resistance. The present 
study reports the rates of nosocomial bacterial resistance 
yielded by this program from 1996 to 1998. 
MATERIALS AND METHODS 
A 2-month point-prevalence study was conducted twice 
yearly (April-May and October-November) from 1996 to 
1998 by 27 Argentinean centers. Antimicrobial suscepti- 
bility data of clinically relevant isolates from inpatients 
(248hr hospitalization) were collected on a computerized 
system (SIR) designed by a member (C. Bantar) of the 
Antimicrobial Committee. Sex, age, hospital ward, and the 
type of specimen were recorded for every patient. Under- 
lying clinical condition, source and type of the infection, 
as well as previous antimicrobial therapy were also 
recorded when available. For calculation of resistance 
rates, the system excluded duplicate isolates (i.e., an iso- 
late of the same bacterial species with the same suscep- 
tibility pattern in the same patient, whatever the isolation 
site, within a Gmo period). 
Organisms were identified according to standard pro- 
cedures.* Susceptibility testing was carried out by the 
disk diffusion method following the National Committee 
for Clinical Laboratory Standards (NCCLS) guidelines9 
Ampicillin, ampicillin-sulbactam, cephalothin, cefoxitin, 
piperacillin, piperacillin-tazobactam, cefotaxime, cef- 
tazidime, cefepime, imipenem, ciprofloxacin, trimetho- 
prim-sulfamethoxazole, gentamicin, and amikacin were 
tested against gram-negative rods. Penicillin, oxacillin, ery- 
thromycin, trimethoprim-sulfamethoxazole, rifampin, 
minocycline, ciprofloxacin, gentamicin, vancomycin, and 
teicoplanin were assayed against staphylococci, whereas 
the enterococci were tested for detection of resistance 
to ampicillin, nitrofurantoin, vancomycin, teicoplanin, 
ciprofloxacin, and high levels of gentamicin and strep- 
tomycin. Staphylococcus aureus ATCC 25923, 
Escherichia coli, both ATCC 35218 and ATCC 25922, 
Enterococcus faecalis ATCC 29212, and Pseudomonas 
aeruginosa ATCC 27853 were used as the controls. 
RESULTS 
In all, 6343 isolates recovered from 5603 inpatients were 
included. The overall species distribution (%) of the iso- 
lates collected during the point-prevalence studies per- 
formed from 1996 to 1998 was as follows: S. aureus, 
22.7%; E. coli, 18.3%; Paeruginosa, 13.4; coagulase-nega- 
tive staphylococci (CNS), 9.4% (includes Staphylococcus 
epidermidis [38%] and other species [62%]); Klebsiella 
pneumoniae, 9.2%; Enterococcus spp, 7.2% (includes E. 
faecalis [68%], Enterococcus faecium [6.3%], and Ente- 
rococcus sp [27%]); Acinetobacter spp, 5.9%; Enterobac- 
ter cloacae, 4.6%; Proteus mirabilis, 3.3%; Serratia 
marcescens, 1.3%, and other species, 4.7%. 
Figure 1 shows the frequency of the different species 
recovered from blood cultures of all the patients enrolled 
in the two prevalence studies performed in 1998. The 
most relevant differences, with the relative frequency of 
the species recovered from all the specimens collected 
between 1996 and 1998 (overall prevalence), were found 
in E. coli and l? aeruginosa, which declined from ranks 
2 and 3 among the overall prevalence to ranks 5 and 6 
in blood cultures, respectively. By contrast, K. pneumo- 
niae and E. cloacae rose from ranks 5 and 9 to ranks 3 
and 4, respectively. Staphylococci accounted for nearly 
one-half of all nosocomial bacteremias (42%). In fact, CNS 
rose from rank 4 in overall prevalence to rank 1 in blood 
cultures. 
Table 1 presents the resistance profiles of the Enter- 
obacteriaceae species, most frequently recovered. 
Although a high rate of resistance was displayed by all 
species against the majority of the drugs, the most remark- 
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Figure 1. Species distribution in bloodstream infection from patients 
hospitalized in Argentina during 1998. 
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Table 1. Resistance Profiles of the Enterobacteriaceae Species Most Frequently 
Recovered between 1996 and 1998 from Hospitalized Patients in Argentina 
Percentage of Resistance Displayed by the Following Species* 
E. coli P. mirabilis K. pneumoniae E. cloacae S. marcescens 
Drug (n = 1164) (n =211) (n = 586) (n = 293) (n = 83) 
Ampicillin 63 59 NA NA NA 
Ampicillin-sulbactam 43 43 70 NA NA 
Cephalothin 33 39 66 NA NA 
Cefoxitin 8.5 10 16 NA NA 
Cefotaxime 8 26 48 67 19 
Ceftazidime 6 8.5 42 63 13 
Cefepime 6 13.5 37 33 5 
Piperacillin 40 39 68 50 29 
Piperacilin-tazobactam 11 5 43 45 19.5 
lmipenem 0 0 1 5 0 
Trimethoprim-sulfamethoxazole 36 50 36 43 26 
Gentamicin 15 38 54 46 20 
Amikacin 7 10 41 31 19 
Ciprofloxacin 13 24 18 38 6 
*All E co/i, P mirabilis, and K. oneumoniae strains resistant to anv extended-soectrum cephalosporin were considered as clinically resistant to all p-lactams, with the 
exception of imipenem 
NA = not applicable. 
cephalothin, and extended-spectrum cephalosporins by 
E. coli, I? mirabilis, and K. pneumoniae. In addition, an 
appreciable rate of resistance to ciprofloxacin was 
observed in all the Enterobacteriaceae species. Further- 
more, a worrisome emerging resistance to imipenem was 
detected in K. pneumoniae and E. cloacae. 
Resistance patterns of I? aeruginosa and Acineto- 
batter spp are depicted in Table 2. Because i? aerugi- 
nosa was one of the most prevalent pathogens isolated 
both from all wards and from the intensive care unit 
(KU), a comparative analysis of resistance rates between 
the ICU and all the ward settings was performed for this 
species. Increased resistance rates showed by strains 
recovered from the ICU versus those displayed by iso- 
lates from all wards showed statistical significance with 
all antibiotics (P < 0.05, x2 test). The most pronounced 
difference was observed in the imipenem resistance, 21% 
versus 36% in all wards and ICU, respectively. Imipenem 
and cefepime were the most active antibiotics against I? 
aeruginosa in all wards (21% and 25% resistance, respec- 
tively). However, no drugs proving effective against more 
than 65% of the strains were shown in the ICU setting 
(i.e., the lowest resistance rate in the ICU was 36%). 
Imipenem was the only antibiotic exhibiting suitable in 
vitro activity against Acinetobacter spp (9% resistance). 
Indeed, none of the other antimicrobial agents assayed 
overcame the 35% susceptibility rate. 
Table 3 shows the resistance profiles of staphylo- 
cocci and enterococci. High rates of oxacillin resistance 
were seen in both S. aureus and CNS (58% and 56%, 
respectively). This resistance was also associated with 
resistance to gentamicin, erythromycin, and, to a lesser 
degree, rifampin, trimethoprim-sulfamethoxazole, and 
ciprofloxacin. Although no strains of staphylococci 
Table 2. Resistance Patterns of Pseudomonas aeruginosa and Acinetobacter spp Strains 
Recovered between 1996 and 1998 from Hospitalized Patients in Argentina 
Percentage of Resistance by the Following Species 
P aeruginosa /solaW from? 
Drug All Wards (n = 850) ICU (n = 206) Acinetobacter spp (n = 375) 
Ampicillin-sulbactam NA NA 65 
Ceftazidime 30 38 
Cefepime 
83 
25 36 83 
lmipenem 21 36 9 
Piperacillin 41 50 92 
Piperacillin-tazobactam 35 43 
Gentamicin 
84 
51 63 83 
Amikacin 36 48 74 
Ciprofloxacin 40 53 83 
“Increased resistance rates shown by F! aeruginosa strains recovered from ICU versus those displayed by isolates from all wards proved statistically significant with all 
antibiotics. 
ICU = intensive care unit: NA = not applicable, 
88 International Journal of Infectious Diseases / Volume 4, Number 2 
Table 3. Resistance Profiles of Staphylococci and Enterococci Strains 
Recovered between 1996 and 1998 from Hospitalized Patients in Argentina 
Percentage of Resistance Displayed by 
Drug S. Aureus (n = 1447) CNS (v = 226) Enterococcus spp* (n = 457) 
Penicillin 95 95 NA 
Ampicillin NA NA a+ 
Oxacillin 58 56 NA 
Erythromycin 56 50 NA 
Rifampin 38 44 NA 
Minocycline 12 5 NA 
Trimethoprim-sulfamethoxazole 40 41 NA 
Vancomycin 0 0 2’ 
Teicoplanin 2 8 21 
Ciprofloxacin 45 31 54 
Nitrofurantoin NA NA 7 
Gentamicin 53 50 33” 
Streptomycin NA NA 375 
*Includes Enterococcus faecalis (n = 305), Enterococcus faecium (n = 29), and Enterococcus sp (n = 123); +no ampicillin resistance was detected in E. faecalis, but in 
95% of the E faecium strains: *glycopeptide resistance was detected only in E. faecium; “high-level resistance. 
CNS = coagulase-negative staphylococci: NA = not assayed. 
displaying decreased susceptibility to vancomycin were 
found, an alarming emergence of teicoplanin resistance 
was observed in both S. aureus and CNS (2% and 8%, 
respectively). Minocycline proved quite active against 
these species (12% and 5% resistance, respectively). No 
ampicillin resistance was detected in E. faecalis, whereas 
this feature was observed in 95% of the E. faecium strains. 
The high-level gentamicin resistance rates were 33% and 
70%, respectively. The overall acquired glycopeptide resis 
tame in enterococci was 2%, albeit such a resistance was 
shown only by E. faecium. In fact, 9 of 29 strains (31%) 
reported as E. faecium were resistant to vancomycin. 
DISCUSSION 
Although a clear relation between the overuse of anti- 
biotics and the emergence of bacterial resistance has 
been difficult to establish, there are several recent stud- 
ies suggesting that antibiotic control efforts may decrease 
bacterial resistance and nosocomial infections.1° Unfor- 
tunately, the misuse of antibiotics, and the poor control 
of drug prescriptions, leading to increased bacterial resis- 
tance in developing countries, including Latin America, 
have been described.‘jz” Therefore, the high rates of resis- 
tance yielded by this study are not surprising. 
The high prevalence of Enterobacteriaceae isolates 
resistant to ampicillin-sulbactam may be attributable to an 
overproduction of a broad-spectrum B-lactamase. Bantar 
et al have recently characterized 48 successive E. coli 
strains resistant to amoxicillin-sulbactam recovered from 
oupatients with urinary tract infection in Argentina.” 
These authors found that 96% of the strains harbored a 
TEM-l-like B-lactamase, suggesting that an overproduc- 
tion of this enzyme was responsible for the resistance. 
Whether a similar mechanism may be applicable to K. 
pneumoniae and I? mirabilis in Argentina remains 
unknown. Furthermore, an alarming rate of resistance to 
extended-spectrum cephalosporins was observed in these 
species. The presence of extended spectrum B-lactamases 
in Argentina was frost reported by Casellas et al, in 1989.13 
Two indigenous novel extended spectrum B-lactamases 
in Argentina were described, (XX-M-2 and PER-2.‘*x15 
Recent epidemiologic studies performed by Galas et al 
demonstrated that CTX-M-2 (64-70%) and to a lesser 
degree, SHY-1 derivates (i.e. SHV-2 and SI-IV-5, ll-20%) 
and PER-2 (5-10%) were the most prevalent extended 
spectrum B-lactamases among a number of Argentinean 
Kpneumoniae and E. coli strains.16~17 In addition, these 
extended spectrum B-lactamases also have been detected 
within strains of E. cloacae and S. marcescens in up to 
20% of the isolates, but the rank of prevalence among 
these species was PER-2, CTX-M-2, and SHV-1-derivates 
in E. cEoacae and CTX-M-2 and SHV-1 derivates in S. 
marcescens.‘8 This fact is important, since the presence 
of an extended spectrum B-lactamase may be overlapped 
by the current production of a group I B-lactamase in 
these species. Emerging resistance to carbapenems by K. 
pneumoniae and E. cloacae is of concern, since this class 
of antibiotics remains as the only choice in almost one- 
half of Argentinean isolates belonging to these species. 
Studies are ongoing in Argentina to elucidate the mech- 
anism responsible for this resistance. 
Pseudomonus aeruginosa, especially the ICU iso- 
lates, exhibited high resistance rates against most of the 
drugs. Significant differences between all wards and the 
ICU may be attributable, in part, to the increased use of 
antibiotics in the ICU. Indeed, the emergence of antibi- 
otic-resistant i? aencginosa associated with the use of dif- 
ferent antipseudomonal agents recently has been 
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described.19 Although imipenem proved the most active 
drug, resistance rates from all wards and the ICU were as 
high as 2 1% and 36%, respectively. A study performed on 
22 imipenem-resistant I? aeruginosa strains from 
Argentina suggested that this resistance was associated 
with deficient OprD expression.zo 
Acinetobacter spp proved resistant to all the antibi- 
otics tested, with the exception of imipenem. Neverthe- 
less, 9% of strains were shown to be resistant to this drug. 
In fact, a novel plasmid-mediated carbapenemase, ARI-2, 
has been detected in several of these strains isolated from 
one of the centers belonging to the SIR participants 
group.21 
High rates (>50%) of methicillin-resistant staphylo- 
cocci were found in this study This is both a therapeu- 
tic and an economic problem. Indeed, a recent study 
performed in 41 ICUs in the United States demonstrated 
that the overuse of vancomycin was heavily determined 
by a mean resistance rate of 32% in S. au?+eus.22 Although 
no staphylococci strains displaying decreased suscepti- 
bility to vancomycin were found, an alarming emergence 
of teicoplanin resistance was observed in both S. aureus 
and CNS (2% and 8%, respectively). Corso et al have per- 
formed a clonal typing study among 148 isolates of 
methicillin-resistant S. aureus collected by 13 hospitals 
from Argentina. 23 These authors stated that the prevalent 
clone (62% of the isolates) had a pulsed-field gel elec- 
trophoresis pattern similar to that of the Brazilian iso- 
lates, (the clone XI::B::B). This clone also was resistant 
to gentamicin, macrolides, rifampin, tetracycline, trimetho- 
prim-sulfamethoxazole, and ciprofloxacin. 
Ampicillin resistance was not detected in E. faecalis. 
By contrast, 95% of the E. faecium strains exhibited this 
feature. High-level gentamicin resistance in enterococci 
increased to 33% in this study, as compared with the 20% 
of resistance reported by Bantar et al in 1991.24 The first 
enterococcus strain proving acquired glycopeptide resis- 
tance described in Argentina and in Latin America was an 
E. faecium isolate recovered from a child in 1996. The 
strain possessed the vanA gene and was reported in 
1998.25 However, a significant emergence of glycopep- 
tide-resistant enterococci (2%) since 1997 is demonstrated 
in the present study, and the resistance rates continue to 
increase (unpublished data). Glycopeptide resistance was 
detected only in E. faecium and all of the isolates pos- 
sessed the van4 gene (data not shown). 
CONCLUSION 
The alarming rates of resistance found in this study com- 
pel researchers to establish more rational guidelines for 
the use of antimicrobial agents. Furthermore, special 
efforts should be undertaken to definitively establish a 
national program for prevention and control of nosoco- 
mial infections in Argentina. 
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